Journal of microbiology, epidemiology and immunobiologyJournal of microbiology, epidemiology and immunobiologyЖурнал микробиологии, эпидемиологии и иммунобиологии0372-93112686-7613Central Research Institute for Epidemiology1891010.36233/0372-9311-682USUKRMREVIEWSОБЗОРЫReview ArticleImmunological and epidemiological effectiveness of pediatric vaccination against hepatitis A using a single dose of inactivated vaccineИммунологическая и эпидемиологическая эффективность вакцинации детей против гепатита А с применением одной дозы инактивированной вакциныhttps://orcid.org/0000-0001-6853-4154LopatukhinaMariya A.ЛопатухинаМария Александровна
Russian Federation

researcher, Laboratory of molecular epidemiology of viral hepatitis, Central Research Institute of Epidemiology; researcher, Laboratory of viral hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera

н. с. лаб. молекулярной эпидемиологии вирусных гепатитов ЦНИИ Эпидемиологии Роспотребнадзора; н. с. лаб. вирусных гепатитов НИИ вакцин и сывороток им. И.И. Мечникова

lopatukhina@cmd.suhttps://orcid.org/0000-0002-3599-117XKyuregyanKaren K.КюрегянКарен Каренович
Russian Federation

Dr. Sci. (Biol.), Professor of the RAS, Head, Laboratory of molecular epidemiology of viral hepatitis, Central Research Institute of Epidemiology; leading researcher at the Laboratory of viral hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera

д-р биол. наук, профессор РАН, зав. лаб. молекулярной эпидемиологии вирусных гепатитов ЦНИИ Эпидемиологии Роспотребнадзора; в. н. с. лаб. вирусных гепатитов НИИ вакцин и сывороток им. И.И. Мечникова; профессор каф. вирусологии Российской медицинской академии непрерывного профессионального образования

kyuregyan@yandex.ruhttps://orcid.org/0000-0002-6636-6801MikhailovMikhail I.МихайловМихаил Иванович
Russian Federation

Dr. Sci. (Med,), Full Member of the RAS, chief researcher, Laboratory of molecular epidemiology of viral hepatitis, Central Research Institute of Epidemiology; Head, Laboratory of viral hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera; Professor, Department of epidemiology, Belgorod State National Research University

д-р мед. наук, акад. РАН, г. н. с. лаб. молекулярной эпидемиологии вирусных гепатитов ЦНИИ Эпидемиологии» Роспотребнадзора; зав. лаб. вирусных гепатитов НИИ вакцин и сывороток им. И.И. Мечникова; профессор каф. эпидемиологии Белгородского государственного национального исследовательского университета

michmich2@yandex.ruCentral Research Institute of EpidemiologyЦентральный научно-исследовательский институт эпидемиологии РоспотребнадзораMechnikov Research Institute for Vaccines and SeraНаучно-исследовательский институт вакцин и сывороток имени И.И. МечниковаRussian Medical Academy of Continuous Professional EducationРоссийская медицинская академия непрерывного профессионального образованияBelgorod National Research UniversityБелгородский государственный национальный исследовательский университет110820250511202510256266341108202511082025Copyright ©; 2025, Lopatukhina M.A., Kyuregyan K.K., Mikhailov M.I.Copyright ©; 2025, Лопатухина М.А., Кюрегян К.К., Михайлов М.И.2025Lopatukhina M.A., Kyuregyan K.K., Mikhailov M.I.Лопатухина М.А., Кюрегян К.К., Михайлов М.И.https://creativecommons.org/licenses/by/4.0https://microbiol.crie.ru/jour/article/view/18910

Hepatitis A is an acute liver disease caused by the hepatitis A virus (HAV), which can be prevented by means of vaccination. The standard hepatitis A vaccination schedule consists of two doses of inactivated vaccine, but for economic reasons and the purpose of improving vaccination coverage, universal pediatric single-dose vaccination programs have been implemented in certain regions of the world.

The aim of this review is to summarize and analyze published data on the duration of protective antibody levels after a single-dose pediatric immunization, as well as hepatitis A incidence in countries where hepatitis A vaccination is carried out using a single dose of inactivated vaccine.

Recent data from different regions of the world, including the Russian Federation, support the effectiveness of the single-dose hepatitis A vaccination strategy, both in terms of the duration of the immune response and the impact on the incidence rates. However, further studies on the long-term effectiveness of single-dose immunization with inactivated vaccine, as well as continuous hepatitis A surveillance, are necessary to assess the duration of protection and the necessity for booster vaccination later in life

Гепатит А — это острое заболевание печени, вызываемое вирусом гепатита А, которое можно предотвратить с помощью вакцинации. Стандартная схема вакцинации против гепатита А предполагает введение двух доз инактивированной вакцины, однако по экономическим соображениям и для повышения уровня охвата вакцинацией в некоторых регионах мира внедрены программы массовой вакцинации детей с применением одной дозы вакцины.

Целью обзора является обобщение и анализ опубликованных данных о длительности сохранения протективных уровней антител после однократной иммунизации детей, а также о заболеваемости в странах, в которых проводится вакцинопрофилактика гепатита А с использованием одной дозы инактивированной вакцины.

Данные последних лет, полученные в разных регионах мира, в том числе в России, подтверждают эффективность стратегии вакцинации против гепатита А с применением одной дозы вакцины как с точки зрения длительности сохранения иммунологического ответа, так и с точки зрения влияния на уровни регистрируемой заболеваемости. Однако для оценки продолжительности защиты и необходимости ревакцинации на более позднем этапе жизни необходимы дальнейшие исследования по долгосрочной эффективности стратегий вакцинации с применением одной дозы инактивированной вакцины, а также непрерывный надзор за гепатитом А.

hepatitis Ahepatitis A vaccinesingle-dose immunizationгепатит Авакцина против гепатита Аоднократная иммунизацияGuo Y., Zhang L., Feng D., et al. The impact of universal live attenuated hepatitis A vaccines in Henan, China, 2005–2018. Int. J. Infect. Dis. 2020;93:163–7. DOI: https://doi.org/10.1016/j.ijid.2020.02.001Stuurman A.L., Marano C., Bunge E.M., et al. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines — A systematic review. Hum. Vaccin. Immunother. 2017;13(3):724–36. DOI: https://doi.org/10.1080/21645515.2016.1242539Lemon S.M., Ott J.J., Van Damme P., Shouval D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J. Hepatol. 2017:S0168-8278(17)32278-X. DOI: https://doi.org/10.1016/j.jhep.2017.08.034Andani A., van Damme P., Bunge E.M., et al. One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review. Vaccine. 2022;40(2):196–205. DOI: https://doi.org/10.1016/j.vaccine.2021.01.038Theeten H., Van Herck K., Van Der Meeren O., et al. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 2015;33(42):5723–7. DOI: https://doi.org/10.1016/j.vaccine.2015.07.008Espul C., Benedetti L., Cuello H., et al. Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina. Hepat. Med. 2012;4:53–60. DOI: https://doi.org/10.2147/HMER.S33847Im J.H., Woo H.T., Ha B., Jung J. Effectiveness of single‐dose administration of inactivated hepatitis A virus vaccination in the Republic of Korea armed forces, 2013‐2016. J. Viral. Hepat. 2020;27(5):537–9. https://doi.org/10.1111/jvh.13249Souto F.J.D., de Brito W.I., Fontes C.J.F. Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil. Vaccine. 2019;37(6):771–5. DOI: https://doi.org/10.1016/j.vaccine.2018.12.054Mikhailov M.I., Lopatukhina M.A., Asadi Mobarhan F.A., et al. Universal single-dose vaccination against hepatitis A in children in a region of high endemicity. Vaccines (Basel). 2020;8(4):780. DOI: https://doi.org/10.3390/vaccines8040780Schmidtke P., Habermehl P., Knuf M., et al. Cell mediated and antibody immune response to inactivated hepatitis A vaccine. Vaccine. 2005;23(44):5127–32. DOI: https://doi.org/10.1016/j.vaccine.2005.06.022Zamir C., Rishpon S., Zamir D., et al. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 2001;20(3):185–7. DOI: https://doi.org/10.1007/s100960100461Iwarson S., Lindh M., Widerström L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J. Travel. Med. 2004;11(2):120–1. DOI: https://doi.org/10.2310/7060.2004.17079Mayorga Pérez O., Herzog C., Zellmeyer M., et al. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J. Infect. Dis. 2003;188(5):671–7. DOI: https://doi.org/10.1086/377309Lolekha S., Pratuangtham S., Punpanich W., et al. Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in Thai children: comparison of three vaccination schedules. J. Trop. Pediatr. 2003;49(6):333–9. DOI: https://doi.org/10.1093/tropej/49.6.333Bravo C., Mege L., Vigne C., Thollot Y. Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric. Expert. Rev. Vaccines. 2019;18(3):209–23. DOI: https://doi.org/10.1080/14760584.2019.1580578Herzog C., Van Herck K., Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence. Hum. Vaccin. Immunother. 2021;17(5): 1496–519. DOI: https://doi.org/10.1080/21645515.2020.1819742Abadia I., Wong D., Rengifo A., et al. Eight years follow-up of the immune response in children after one or two doses of inactivated hepatitis A vaccine in Panama. In: International Pediatric Association (IPA 2019) Congress – 17 to 21 March 2019. Panama City, Panama; 2019.Espul C., Benedetti L., Linares M., et al. Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. Hum. Vaccin. Immunother. 2017;13(11):2707–12. DOI: https://doi.org/10.1080/21645515.2017.1358326Vacchino M.N. Incidence of Hepatitis A in Argentina after vaccination. J. Viral. Hepat. 2008;15(Suppl. 2):47–50. DOI: https://doi.org/10.1111/j.1365-2893.2008.01029.xVizzotti C., González J., Rearte A., et al. Single-dose universal hepatitis A immunization in Argentina: low viral circulation and high persistence of protective antibodies up to 4 years. J. Pediatric Infect. Dis. Soc. 2015;4(4):e62–e67. DOI: https://doi.org/10.1093/jpids/piu068Gentile A. The need for an evidence-based decision-making process with regard to control of hepatitis A. J. Viral. Hepat. 2008;15(Suppl. 2):16–21. DOI: https://doi.org/10.1111/j.1365-2893.2008.01023.xWHO position paper on hepatitis A vaccines – June 2012. Wkly Epidemiol. Rec. 2012;87(28/29):261–76.Urueña A., González J.E., Rearte A., et al. Single-dose universal hepatitis A immunization in one-year-old children in Argentina: High prevalence of protective antibodies up to 9 years after vaccination. Pediatr. Infect. Dis. J. 2016;35(12):1339–42. DOI: https://doi.org/10.1097/INF.0000000000001322Urueña A., Badano M.N., Baré P., et al. Humoral and cellular immune memory response 12 years following single dose vaccination against hepatitis A in Argentinian children. Vaccine. 2022;40(1):114–21. DOI: https://doi.org/10.1016/j.vaccine.2021.11.037de Brito W.I., de Oliveira R.M., Silva J., et al. Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine. J. Viral. Hepat. 2023;30(7):615–20. DOI: https://doi.org/10.1111/jvh.13819Brito W.I., Alves-Junior E.R., Oliveira R.M., Souto F.J.D. Initial evaluation of universal immunization with a single dose against hepatitis A virus in Central Brazil. Braz. J. Infect. Dis. 2018;22(3):166–70. DOI: https://doi.org/10.1016/j.bjid.2018.04.001Lopatukhina M.A., Kyuregyan K.K., Karlsen A.A., et al. The immunological and epidemiological effectiveness of pediatric single-dose vaccination against hepatitis A 9 to 11 years after its implementation in the Tyva Republic, the Russian Federation. Vaccines (Basel). 2024;12(8):907. DOI: https://doi.org/10.3390/vaccines12080907Raczniak G.A., Thomas T.K., Bulkow L.R., et al. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. Vaccine. 2013;31(17):2152–5. DOI: https://doi.org/10.1016/j.vaccine.2013.02.048Vizzotti C., González J., Gentile A., et al. Impact of the single-dose immunization strategy against hepatitis A in Argentina. Pediatr. Infect. Dis. J. 2014;33(1):84–8. DOI: https://doi.org/10.1097/INF.0000000000000042Попова О.Е., Кюрегян К.К., Ильченко Л.Ю. и др. Эпидемиологический и молекулярно-биологический анализ причин подъема заболеваемости гепатитом А в Республике Тыва в 2008 году. Журнал микробиологии, эпидемиологии и иммунобиологии. 2010;(3):23–6. Popova O.E., Kiuregian K.K., Il'chenko L.Iu., et al. Epidemiological and molecular biological analysis of causes of rise of hepatitis A incidence in Republic of Tyva in 2008. Journal of Microbiology, Epidemiology and Immunobiology. 2010;(3):23–6.Blanco Fernández M.D., Torres C., Riviello-López G., et al. Analysis of the circulation of hepatitis A virus in Argentina since vaccine introduction. Clin. Microbiol. Infect. 2012;18(12):E548–51. DOI: https://doi.org/10.1111/1469-0691.12034Yanez L.A., Lucero N.S., Barril P.A., et al. Evidence of hepatitis A virus circulation in central Argentina: seroprevalence and environmental surveillance. J. Clin. Virol. 2014;59(1):38–43. DOI: https://doi.org/10.1016/j.jcv.2013.11.005Fantilli A., Cola G.D., Castro G., et al. Hepatitis A virus monitoring in wastewater: a complementary tool to clinical surveillance. Water Res. 2023;241:120102. DOI: https://doi.org/10.1016/j.watres.2023.120102Jeong S.H., Lee H.S. Hepatitis A: clinical manifestations and management. Intervirology. 2010;53(1):15–9. DOI: https://doi.org/10.1159/000252779Sabrià A., Gregori J., Garcia-Cehic D., et al. Evidence for positive selection of hepatitis A virus antigenic variants in vaccinated men-having-sex-with men patients: implications for immunization policies. EBioMedicine. 2019;39:348–57. DOI: https://doi.org/10.1016/j.ebiom.2018.11.023